Floatz logo

Serplulimab

Small Cell Lung Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltdmonoclonal_antibodyPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
65/ 100

Competitive context

276 Active assets in the Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
Berzosertib
National Cancer Institute (NCI)
Phase 2BBB
ANTI-PD-L1 MONOCLONAL ANTIBODY SHR-1316
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Etoposide
Sichuan University
Phase 4BBB
Cis-Diamminedichloroplatinum Ii
National Cancer Institute (NCI)
Phase 4BBB

View all 50 →

Same molecule, other indications

Serplulimab is also rated in:

non-small cell squamous lung carcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →
non-small cell lung carcinomaActive
BB
Indicative · Phase 2/3
67 / 100
View asset →
malignant pancreatic neoplasmActive
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →